Abstract:<div class="abstract-group"> <section class="article-section article-section__abstract" lang="en" data-lang="en" id="section-1-en"> <h3 class="article-section__header main abstractlang_en main">Abstract</h3> <div class="article-section__content en main"> <div class="article-section__content" id="jor24227-sec-0001"> <p>Mutant TP53 is a promising therapeutic target in cancers. Considering the current challenges facing the clinical treatment of cancer, as well as the urgent need to identify novel therapeutic targets in osteosarcomas, we aimed to evaluate the clinical significance of mutant TP53 in osteosarcoma patients and to explore the therapeutic effect of targeting mutant TP53 in osteosarcomas. We performed a meta‐analysis to investigate the relationship between mutant TP53 and the overall survival of patients with osteosarcoma. A CRISPR‐Cas9 system and a TP53 inhibitor, NSC59984, were also used to specifically knock‐out and inhibit mutant TP53 in the human osteosarcoma cell lines, KHOS and KHOSR2. The meta‐analysis demonstrated that mutations in the TP53 gene could be used to predict a poor 2‐year survival in osteosarcoma patients. We also demonstrated that the expression of mutant TP53 in human osteosarcoma cell lines can be efficiently knocked‐out using CRISPR‐Cas9, and this decreased the proliferation, migration, and tumor formation activity of these osteosarcoma cells. Moreover, drug sensitivity to doxorubicin was increased in these TP53 knock‐out osteosarcoma cells. NSC59984 also showed similar anti‐tumor effects as CRISPR‐Cas9 targeted TP53 in the osteosarcoma cells <i>in vitro</i>. We have also demonstrated that the knock‐out or inhibition of mutant TP53 decreased the expression of the oncogene IGF‐1R, anti‐apoptotic proteins Bcl‐2 and Survivin in osteosarcoma cells. Collectively, these results suggest that mutant TP53 is a promising therapeutic target in osteosarcomas. Therefore, further studies exploring novel strategies to target mutant TP53 may help improve the treatment outcomes of osteosarcoma patients in the clinic. This article is protected by copyright. All rights reserved </p>

Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis

Anticarin-beta shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis

The Role of CTLA-4 and PD-1 in Anti-Tumor Immune Response and Their Potential Efficacy Against Osteosarcoma

CD47 Blockade Inhibits Tumor Progression Human Osteosarcoma in Xenograft Models

Anti-CD166/4-1BB Chimeric Antigen Receptor T Cell Therapy for the Treatment of Osteosarcoma

Icariin Inhibits Growth Of Human Osteosarcoma Cells By Inducing Apoptosis Via Downregulation Of Beta-Catenin Signaling

A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors.

Abstract 7156: Targeting the β-catenin signaling axis in osteosarcoma

Down Regulation Of Human Positive Coactivator 4 Suppress Tumorigenesis And Lung Metastasis Of Osteosarcoma

Targeting the CK1α/CBX4 Axis for Metastasis in Osteosarcoma.

Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway.

Targeting the Wnt/β-catenin pathway in human osteosarcoma cells

Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway

Cantharidin inhibits osteosarcoma proliferation and metastasis by directly targeting miR-214-3p/DKK3 axis to inactivate β-catenin nuclear translocation and LEF1 translation

The Iron Chelator Dp44mt Suppresses Osteosarcoma'S Proliferation, Invasion and Migration: in Vitro and in Vivo

Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma

Small Molecule TSC01682 Inhibits Osteosarcoma Cell Growth by Specifically Disrupting the CUL4B-DDB1 Interaction and Decreasing the Ubiquitination of CRL4B E3 Ligase Substrates.

Cinobufacini injection suppresses the proliferation of human osteosarcoma cells by inhibiting PIN1-YAP/TAZ signaling pathway

Targeting the Anaphase-Promoting Complex/cyclosome (APC/C)- Bromodomain Containing 7 (BRD7) Pathway for Human Osteosarcoma

Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A

Discovery of 2-Amino-3-cyanothiophene Derivatives As Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis.